Announcement of strengthened collaboration with Reimei Co., Ltd. toward practical application in the field of Regenerative medicine

Background and purpose of the agreement

Driven by our desire to "contribute to the well-being of people and society," we have been striving to realize medical and healthcare services that are tailored to various stages of life. Regenerative medicine is a medical treatment that aims to restore bodily functions impaired by injury or disease through the power of cells, and is an important medical field that can provide new treatment options for diseases for which no adequate treatments have been established. We have consistently covered everything from research to manufacturing and clinical trials, and have been working to maximize the power of cells, including process development, formulation design, quality evaluation, and consideration of administration methods.
Now, as Raymay, with which we have had a capital relationship regarding Regenerative medicine technology, has progressed to a stage where clinical application and practical use are in sight, we have made an additional investment as part of our efforts to accelerate our Regenerative medicine business, and will further strengthen our collaboration toward commercialization.
Reimei is a company focused on commercializing research results using iPS cells, a field of research led by Professor Koji Nishida of the Department of Ophthalmology at Osaka University Graduate School of Medicine. The company holds exclusive licenses to Osaka University's SEAM method and aims to establish an iPS cell-derived corneal Regenerative medicine business, using allogeneic iPS cells to steadily supply high-quality human iPS cell-derived corneal epithelial cell sheets and corneal endothelial cells with reduced rejection. Clinical studies have confirmed safety and provided support for efficacy, with the results published online in the British scientific journal The Lancet on November 8, 2024. As of January 2026, a corporate clinical trial has begun for corneal epithelial stem cell exhaustion syndrome (CES), a pivotal trial to ultimately evaluate safety and efficacy, with progress toward obtaining marketing approval.
We will work with Reimei to manufacture and sell corneal epithelial cell sheets in the Japanese market. By providing a stable supply of allogeneic cell sheets, we aim to commercialize the technology in collaboration with Reimei, providing a new treatment option for patients who require corneal transplants but are currently receiving inadequate treatment.

"Reimei Co., Ltd." Company Profile

Future outlook

At present, we expect the impact of this matter to be minor on our consolidated financial results for the fiscal year ending March 31, 2026. We will promptly announce any specific initiatives or matters that require announcement in the future.